Slow Capital Inc. Makes New Investment in BeOne Medicines Ltd. – Sponsored ADR $ONC

Slow Capital Inc. bought a new position in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 18,083 shares of the company’s stock, valued at approximately $4,377,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of ONC. Farther Finance Advisors LLC bought a new stake in BeOne Medicines during the second quarter worth $39,000. Signaturefd LLC acquired a new stake in shares of BeOne Medicines in the 2nd quarter valued at approximately $49,000. Parallel Advisors LLC acquired a new position in BeOne Medicines during the 2nd quarter worth approximately $59,000. Avanza Fonder AB bought a new position in BeOne Medicines in the 2nd quarter valued at approximately $199,000. Finally, Aaron Wealth Advisors LLC acquired a new stake in BeOne Medicines in the second quarter valued at approximately $200,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ONC. Morgan Stanley boosted their price target on BeOne Medicines from $313.00 to $330.00 and gave the stock an “overweight” rating in a report on Friday, June 27th. Barclays assumed coverage on shares of BeOne Medicines in a research note on Thursday, September 18th. They set an “overweight” rating and a $385.00 price target for the company. JPMorgan Chase & Co. lifted their target price on BeOne Medicines from $321.00 to $345.00 and gave the stock an “overweight” rating in a report on Thursday, July 17th. Zacks Research raised BeOne Medicines from a “hold” rating to a “strong-buy” rating in a research note on Thursday, September 18th. Finally, Royal Bank Of Canada lifted their price objective on BeOne Medicines from $349.00 to $364.00 and gave the stock an “outperform” rating in a research note on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, BeOne Medicines has an average rating of “Moderate Buy” and an average price target of $336.30.

BeOne Medicines Price Performance

Shares of NASDAQ ONC opened at $344.53 on Tuesday. The company has a current ratio of 1.95, a quick ratio of 1.72 and a debt-to-equity ratio of 0.04. The firm has a market cap of $37.76 billion, a price-to-earnings ratio of -199.15 and a beta of 0.31. BeOne Medicines Ltd. – Sponsored ADR has a 1-year low of $170.99 and a 1-year high of $355.30. The stock has a fifty day simple moving average of $319.57 and a two-hundred day simple moving average of $274.54.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings results on Wednesday, August 6th. The company reported $0.84 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.36. The firm had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.24 billion. BeOne Medicines had a negative net margin of 3.89% and a negative return on equity of 1.22%. Analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post -5.82 earnings per share for the current year.

Insider Activity

In other BeOne Medicines news, Director Corazon (Corsee) D. Sanders sold 2,665 shares of the firm’s stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $337.00, for a total transaction of $898,105.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Titus B. Ball sold 122 shares of BeOne Medicines stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $326.76, for a total value of $39,864.72. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 181,315 shares of company stock valued at $54,839,498. Corporate insiders own 6.62% of the company’s stock.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.